Co-Authors
This is a "connection" page, showing publications co-authored by Benjamin Pinsky and James Zehnder.
Connection Strength
3.917
-
Ultra-sensitive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection for the Diagnosis of Coronavirus Disease 2019 (COVID-19) in Upper Respiratory Samples. Clin Infect Dis. 2021 12 16; 73(12):2326-2328.
Score: 0.246
-
Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance. J Clin Microbiol. 2021 Jul 19; 59(8):e0085921.
Score: 0.239
-
Case-Control Study of Individuals with Discrepant Nucleocapsid and Spike Protein SARS-CoV-2 IgG Results. Clin Chem. 2021 07 06; 67(7):977-986.
Score: 0.239
-
A SARS-CoV-2 Variant with L452R and E484Q Neutralization Resistance Mutations. J Clin Microbiol. 2021 06 18; 59(7):e0074121.
Score: 0.238
-
High Frequency of SARS-CoV-2 RNAemia and Association With Severe Disease. Clin Infect Dis. 2021 05 04; 72(9):e291-e295.
Score: 0.236
-
Evaluation of SARS-CoV-2 total antibody detection via a lateral flow nanoparticle fluorescence immunoassay. J Clin Virol. 2021 06; 139:104818.
Score: 0.234
-
Combined SARS-CoV-2 nucleic acid amplification testing and respiratory virus panel RT-PCR on the Hologic Panther Fusion system. J Clin Virol. 2021 05; 138:104792.
Score: 0.233
-
Strand-Specific Reverse Transcription PCR for Detection of Replicating SARS-CoV-2. Emerg Infect Dis. 2021 Feb; 27(2):632-635.
Score: 0.232
-
Large-Scale Testing of Asymptomatic Healthcare Personnel for Severe Acute Respiratory Syndrome Coronavirus 2. Emerg Infect Dis. 2021 Jan; 27(1).
Score: 0.229
-
Performance of Nucleic Acid Amplification Tests for Detection of Severe Acute Respiratory Syndrome Coronavirus 2 in Prospectively Pooled Specimens. Emerg Infect Dis. 2021 Jan; 27(1).
Score: 0.228
-
Comparison of a Point-of-Care Assay and a High-Complexity Assay for Detection of SARS-CoV-2 RNA. J Appl Lab Med. 2020 11 01; 5(6):1307-1312.
Score: 0.228
-
Comparison of the Accula SARS-CoV-2 Test with a Laboratory-Developed Assay for Detection of SARS-CoV-2 RNA in Clinical Nasopharyngeal Specimens. J Clin Microbiol. 2020 Jul 23; 58(8).
Score: 0.223
-
Retrospective Screening for SARS-CoV-2 RNA in California, USA, Late 2019. Emerg Infect Dis. 2020 Oct; 26(10):2487-2488.
Score: 0.223
-
Comparison of a laboratory-developed test targeting the envelope gene with three nucleic acid amplification tests for detection of SARS-CoV-2. J Clin Virol. 2020 08; 129:104427.
Score: 0.220
-
Five-minute point-of-care testing for SARS-CoV-2: Not there yet. J Clin Virol. 2020 07; 128:104410.
Score: 0.220
-
Comparison of the Panther Fusion and a laboratory-developed test targeting the envelope gene for detection of SARS-CoV-2. J Clin Virol. 2020 06; 127:104383.
Score: 0.220
-
Plasma as an alternative COVID-19 diagnostic specimen in a hospitalized patient negative for SARS-CoV-2 by nasopharyngeal swab. Diagn Microbiol Infect Dis. 2021 Jul; 100(3):115365.
Score: 0.058
-
Occurrence and Timing of Subsequent Severe Acute Respiratory Syndrome Coronavirus 2 Reverse-transcription Polymerase Chain Reaction Positivity Among Initially Negative Patients. Clin Infect Dis. 2021 01 27; 72(2):323-326.
Score: 0.058
-
Defining the features and duration of antibody responses to SARS-CoV-2 infection associated with disease severity and outcome. Sci Immunol. 2020 12 07; 5(54).
Score: 0.057
-
Persistent detection of SARS-CoV-2 RNA in patients and healthcare workers with COVID-19. J Clin Virol. 2020 08; 129:104477.
Score: 0.055